Thomas J. Rutherford MD, PhD

Professor of Obstetrics, Gynecology, and Reproductive Sciences

Specialties & Subspecialties

Obstetrics, Gynecology & Reproductive Sciences: Gynecologic Oncology | Ovarian Cancer Program, Early Detection

Education & Training

  • Ph.D., Medical College of Ohio (1986)
  • M.D., Medical College of Ohio (1989)
  • Resident, Cooper Hospital , Obstetrics & Gynecology
  • Fellow, Cooper Hospital , Obstetrics & Gynecology
  • Fellow, Yale University School of Medicine , Gynecology Oncology

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients

Clinical Interests

Ovarian; uterine; vaginal; cervical and vulvar cancer; Difficult gynecologic surgery; Trophoblastic neoplasia; Unknown primary cancer; Brachytherapy; Gestational trophoblastic neoplasia

Cancers Treated

Brachytherapy, Cervix, Gestational Trophoblastic Neoplasia, Ovary, Unknown primary, Uterus, Vagina & Vulva

Board Certifications

  • Gynecologic Oncology, Board Certified (2000)
  • Obstetrics & Gynecology, Board Certified (1997)

Clinical Trials

ConditionsStudy Title
Chordoma, Desmoid Tumor, Adult Rhabdomyosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Metastatic Childhood Soft Tissue Sarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, and Soft TissueA COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol (COG 9902)
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.
Novel Treatment to Enhance Smoking Cessation before Cancer Surgery

More Clinical Trials...

Edit Profile